|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 656.01 USD | +0.63% |
|
-3.06% | -15.01% |
| 25/07 | US FDA approves Outlook Therapeutics' eye disease drug | RE |
| 24/07 | Sanofi to Drop Eczema Drug Amid Review of Pipeline Under New CEO | DJ |
| Market Cap | 66.74B 58.73B 54.57B 50.11B 94.05B 6,445B 95.63B 648B 253B 3,159B 251B 245B 10,932B | P/E 2026 * |
17.3x | P/E 2027 * | 13.8x |
|---|---|---|---|---|---|
| Enterprise Value | 58.92B 51.84B 48.18B 44.24B 83.03B 5,689B 84.42B 572B 223B 2,789B 221B 216B 9,650B | EV / Sales 2026 * |
3.71x | EV / Sales 2027 * | 3.19x |
| Free-Float |
72.33% | Yield 2026 * |
0.59% | Yield 2027 * | 0.67% |
Last Transcript: Regeneron Pharmaceuticals, Inc.
| 1 day | +0.63% | ||
| 1 week | -3.06% | ||
| Current month | +5.21% | ||
| 1 month | +5.23% | ||
| 3 months | -12.71% | ||
| 6 months | -12.94% | ||
| Current year | -15.01% |
| 1 week | 637.8 |  | 681.74 |
| 1 month | 622.29 | | 691.13 |
| Current year | 591.52 | | 821.11 |
| 1 year | 541 | | 821.11 |
| 3 years | 476.49 | | 1,211.2 |
| 5 years | 476.49 | | 1,211.2 |
| 10 years | 271.37 | | 1,211.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 66 | 01/01/2001 | |
| Chief Executive Officer | 73 | 08/01/1988 | |
| Director of Finance/CFO | 55 | 05/02/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 09/06/2023 | |
Michael Brown
BRD | Director/Board Member | 85 | 01/06/1991 |
Joseph Goldstein
BRD | Director/Board Member | 85 | 01/06/1991 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 2/7/26 | Sell | Director | -200 | 0.0002% | ||
| 1/5/26 | Sell | Director | -100 | 0.0001% | ||
| 1/4/26 | Sell | Director | 100 | 0.0001% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.63% | -3.06% | +16.18% | -9.78% | 66.74B | |
| +1.23% | +2.80% | +37.51% | +202.14% | 53.32B | |
| +10.08% | +51.80% | +51.80% | +51.80% | 48.12B | |
| -1.32% | -7.38% | -57.63% | -57.10% | 38.25B | |
| +0.78% | -1.84% | +52.49% | -27.01% | 29.85B | |
| +0.84% | +0.36% | +66.93% | +85.42% | 23.51B | |
| -5.17% | -12.54% | +58.98% | -56.04% | 21.45B | |
| -1.21% | +1.12% | +1.98% | +170.93% | 19.97B | |
| -0.22% | -0.95% | +61.97% | +123.78% | 16.38B | |
| +1.31% | +3.24% | +84.01% | +152.77% | 16.47B | |
| Average | +0.70% | -0.57% | +37.42% | +63.69% | 33.41B | |
| Weighted average by Cap. | +1.40% | +0.06% | +30.57% | +55.05% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 15.87B 13.97B 12.98B 11.92B 22.37B 1,533B 22.74B 154B 60.2B 751B 59.58B 58.3B 2,600B | 17.61B 15.49B 14.4B 13.22B 24.81B 1,700B 25.23B 171B 66.78B 833B 66.1B 64.67B 2,884B |
| Net income | 3.98B 3.5B 3.25B 2.99B 5.6B 384B 5.7B 38.62B 15.08B 188B 14.93B 14.61B 651B | 5.03B 4.42B 4.11B 3.77B 7.08B 485B 7.2B 48.8B 19.06B 238B 18.86B 18.46B 823B |
| Net Debt | -7.82B -6.88B -6.4B -5.87B -11.02B -755B -11.21B -75.97B -29.67B -370B -29.37B -28.73B -1,281B | -10.51B -9.25B -8.6B -7.89B -14.81B -1,015B -15.06B -102B -39.87B -498B -39.46B -38.61B -1,722B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24/07/26 | USD 656.01 | +0.63% | 708,392 |
| 23/07/26 | USD 651.91 | +0.11% | 1,129,411 |
| 22/07/26 | USD 651.18 | -3.56% | 872,170 |
| 21/07/26 | USD 675.19 | +0.45% | 529,783 |
| 20/07/26 | USD 672.15 | -0.67% | 624,791 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- REGN Stock
Select your edition
All financial news and data tailored to specific country editions
